Imsidolimab for the treatment of generalized pustular psoriasis
- PMID: 37459129
- DOI: 10.1093/bjd/ljad203
Imsidolimab for the treatment of generalized pustular psoriasis
Comment on
-
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.Br J Dermatol. 2023 Jul 17;189(2):161-169. doi: 10.1093/bjd/ljad083. Br J Dermatol. 2023. PMID: 37120722 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
